ArticleBiomedicines2026
BRAF V600E/TERT Promoter Co-Mutation Is Associated with Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Translational Molecular Biomarker Study.
Madina A Mussulmanova, Laura A Pak, Aidana M Rakhmankulova, Arailym Baurzhan, Lyudmila M Pivina, Diana A Pak, Zhandos K Burkitbayev, Andrey Yu Orekhov, Azhar S Baktiyar, Saltanat O Bolsynbekova and 1 more
Abstract read
In one paragraphArticle in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Madina A MussulmanovaDepartment of Clinical Oncology, Radiology, and Nuclear Medicine named after Professor D.R. Musinov, Semey Medical University, Semey 071400, Kazakhstan.
Laura A PakOffice of the Chairman of the Management Board, National Research Oncology Center, Astana 010000, Kazakhstan.ORCID 0000-0002-5249-3359 Aidana M RakhmankulovaDepartment of Clinical Oncology, Radiology, and Nuclear Medicine named after Professor D.R. Musinov, Semey Medical University, Semey 071400, Kazakhstan.ORCID 0000-0003-3307-413X Arailym BaurzhanCenter of Endoscopy and Functional Diagnostics, Center of Nuclear Medicine and Oncology, Semey 071400, Kazakhstan.
Lyudmila M PivinaDepartment of Emergency Medicine, Semey Medical University, Semey 071400, Kazakhstan.ORCID 0000-0002-8035-4866 Diana A PakDepartment of Pediatrics, Astana Vision, Astana 010000, Kazakhstan.
Zhandos K BurkitbayevOffice of the Chairman of the Management Board, National Research Oncology Center, Astana 010000, Kazakhstan.
Andrey Yu OrekhovDepartment of Internal Medicine, Semey Medical University, Semey 071400, Kazakhstan.
Azhar S BaktiyarDepartment of Radionuclide Therapy, Center of Nuclear Medicine and Oncology, Semey 071400, Kazakhstan.
Saltanat O BolsynbekovaCenter of Cytopathomorphology, Immunohistochemistry, and Translational Oncology, National Research Oncology Center, Astana 010000, Kazakhstan.ORCID 0009-0002-2462-1883 Masahiro NakashimaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0002-9036-8735 Funding
Ministry of Science and Higher Education of the Republic of Kazakhstan grant AP23488193 "Optimization of the management system for radioiodine-resistant thyroid cancer in Kazakhstan, considering individual clinicopathological and molecular characteristics"
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
BRAFdifferentiated thyroid cancerKazakh populationmolecular biomarkerradioiodine-refractory thyroid cancerTERT promoterthyroid cancer prognosis
Identifiers
PMID42512104
PMCPMC13406640
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390